triumph-3 retatrutide The numbers from Lilly's Phase 3 trial dropped this week and I haven't been able to stop thinking about them. Not only as a doctor but as a long-term GLP-1 user Retatrutide Explained: Mechanism, Phase 3

Youre simply targeting the soft, pinchable layer of fat that most people have in their abdomen, thighs, or upper arms

Safety verification remains critical when pursuing cost-saving alternatives

Weight regain of 15+ lbs from lowest post-surgical weight Plateau before reaching goal weight despite adherence Persistent hunger that interferes with maintenance At least 12-18 months post-surgery Willing to commit to monitoring and follow-up No contraindications to GLP-1 class medications Less Ideal Candidates Patients within their first year post-surgery generally should not start Retatrutide

Retatrutide (LY3437943) is a first-in-class triple-receptor agonist peptide developed by Eli Lilly that simultaneously activates three metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon

February 17, 2025 16:44 View More Is Your Thyroid Really the Problem

She has a doctorate in exercise science and has conducted research on womens health, exercise and bone density for more than 35 years